Literature DB >> 8410999

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

C H Mitch1, J D Leander, L G Mendelsohn, W N Shaw, D T Wong, B E Cantrell, B G Johnson, J K Reel, J D Snoddy, A E Takemori.   

Abstract

A series of (3R*,4R*)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists with varying substituents on the nitrogen were evaluated for their effect on food consumption in obese Zucker rats. Opioid affinity (mu, kappa, and delta for selected compounds) and opioid antagonist activity (mu and kappa) were characterized and compared to effects on food consumption. No compounds with high selectivity for either mu or kappa receptors were discovered. However, compounds in the series had exceptional potency as opioid antagonists and in reducing food consumption in the obese Zucker rat. In contrast, a few compounds with high potency as opioid antagonists had much weaker potency for inhibiting food consumption. (3R,4R)-3,4-Dimethyl-1-[(3S)-3- hydroxy-3-cyclohexyl-propyl]-4-(3-hydroxyphenyl)piperidine (11,LY255582) emerged as having the best activity profile, both in reducing food consumption and as an opioid antagonist. Compound 11 is a highly potent mu, kappa-, and delta-opioid antagonist with possible clinical utility as an appetite suppressant for weight loss.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410999     DOI: 10.1021/jm00072a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

2.  Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.

Authors:  Chad M Kormos; Chunyang Jin; Juan Pablo Cueva; Scott P Runyon; James B Thomas; Lawrence E Brieaddy; S Wayne Mascarella; Hernán A Navarro; Brian P Gilmour; F Ivy Carroll
Journal:  J Med Chem       Date:  2013-05-16       Impact factor: 7.446

Review 3.  The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.

Authors:  F Ivy Carroll; Roland E Dolle
Journal:  ChemMedChem       Date:  2014-06-30       Impact factor: 3.466

4.  1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.

Authors:  F Ivy Carroll; Juan Pablo Cueva; James B Thomas; S Wayne Mascarella; Scott P Runyon; Hernán A Navarro
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

Review 5.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

6.  4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

Authors:  F Ivy Carroll; Moses G Gichinga; John D Williams; Eyal Vardy; Bryan L Roth; S Wayne Mascarella; James B Thomas; Hernán A Navarro
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

7.  Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.

Authors:  Nurulain T Zaveri; V Blair Journigan; Willma E Polgar
Journal:  ACS Chem Neurosci       Date:  2015-02-18       Impact factor: 4.418

8.  Effect of the 3- and 4-methyl groups on the opioid receptor properties of N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines.

Authors:  Chad M Kormos; Juan Pablo Cueva; Moses G Gichinga; Scott P Runyon; James B Thomas; Lawrence E Brieaddy; S Wayne Mascarella; Brian P Gilmour; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2014-03-26       Impact factor: 7.446

Review 9.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.